Click on a filter below to refine your search. Remove a filter to broaden your search.
An increased risk for Alzheimer’s disease and related dementia was seen in association with higher and lower versus middle quintile of HDL-C.
Two trials show a lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks.
Objectively assessed VMS (so-called hot flashes), including sleep VMS, are associated with significantly lower amyloid-β42/40.